* ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

* CELLECTIS IS WORKING CLOSELY WITH THE INVESTIGATORS AND THE FDA IN ORDER TO RESUME THE TRIALS WITH AN AMENDED PROTOCOL INCLUDING A LOWERED DOSING OF UCART123 Source text for Eikon: Further company coverage: (Gdynia Newsroom)